GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1Results posted

A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants

A Drug-Drug Interaction, Single-arm, Open-label Study to Assess the Effect of Quinidine on the Pharmacokinetics of Orforglipron in Healthy Participants

Lead sponsor

Eli Lilly and Company

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 18.5-35•Healthy volunteers

Primary endpoints

•AUC•PK: Maximum Observed Concentration (Cmax) of Orforglipron•AUC of Orforglipron

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06704763

Org study ID27312

Secondary IDJ2A-MC-GZPPEli Lilly and Company

Timeline

Milestones

Study first posted2024-11-26actual

Study start2024-12-06actual

Primary completion2025-02-05actual

Study completion2025-02-05actual

Last update posted2026-05-26actual

Results first posted2026-05-26actual

Assets

Investigational agents

Orforglipron

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age21 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and electrocardiogram (ECG)

•Have a hemoglobin level of:

–at least 11.4 grams per deciliter (g/dL) for individuals assigned female at birth (AFAB), and

–at least 12.5 g/dL for individuals assigned male at birth (AMAB)

•Have a body weight equal to or greater than 45 kilograms (kg), and a body mass index within the range of 18.5 to 35.0 kilogram per square meter (kg/m²) at screening

Exclusion criteria

•Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, psychological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting risk when taking orforglipron, midazolam, or quinidine; or interfering with the interpretation of data

•Have a 12 lead electrocardiogram (ECG) abnormality, including known prolongation of QT/QTc interval, significant bradycardia, significant heart blocks or a history of any risk factors for ventricular arrhythmia, heart failure, hypokalemia or hypomagnesemia, or other factors that, in the opinion of the investigator, increases the risks associated with participating in the study

•Have an abnormal blood pressure or pulse rate, deemed to be clinically significant by the investigator

•Have a history of benign ethnic neutropenia

•Have a GI disease or disorder, such as relevant esophageal reflux or gall bladder disease, which could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or impacts gastric emptying, for example gastric bypass surgery or pyloric stenosis, except for appendectomy

•Have a history or presence of pancreatitis, including chronic pancreatitis or idiopathic acute pancreatitis

•Have known allergies to:

–quinidine

–midazolam

–orforglipron

–related compounds, or

–any components of the formulation

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

10 endpoints

Primary/registry result

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Orforglipron

Time frame:Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours post orforglipron dose on days 1, 8

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogram*hour per milliliter	95% CI
Midazolam + Orforglipron + QuinidineDay 1	89.9	—
Day 8	79.1	—

Primary/registry result

PK: Maximum Observed Concentration (Cmax) of Orforglipron

Time frame:Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours post orforglipron dose on days 1, 8

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogram per milliliter	95% CI
Midazolam + Orforglipron + QuinidineDay 1	4.11	—
Day 8	3.06	—

Primary/protocol endpoint

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Orforglipron

Time frame:Baseline to Study Completion (Up to 2 Weeks)

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

PK: Maximum Concentration (Cmax) of Orforglipron

Time frame:Baseline to Study Completion (Up to 2 Weeks)

Cmax

concentration, descriptive

Secondary/registry result

PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Midazolam

Time frame:Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogram*hour per milliliter	95% CI
Midazolam + Orforglipron + QuinidineDay -1	2.06	—
Day 7	2.73	—

Secondary/registry result

PK: Maximum Concentration (Cmax) of Midazolam

Time frame:Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogram per milliliter	95% CI
Midazolam + Orforglipron + QuinidineDay -1	0.725	—
Day 7	0.999	—

Secondary/registry result

PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of 1-Hydroxymidazolam

Time frame:Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogram*hour per milliliter	95% CI
Midazolam + Orforglipron + QuinidineDay -1	0.676	—
Day 7	0.999	—

Secondary/registry result

PK: Maximum Concentration (Cmax) of 1-Hydroxymidazolam

Time frame:Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogram per milliliter	95% CI
Midazolam + Orforglipron + QuinidineDay -1	0.224	—
Day 7	0.343	—

Secondary/protocol endpoint

PK: AUC of Midazolam

Time frame:Baseline to Study Completion (Up to 2 Weeks)

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

PK: Cmax of Midazolam

Time frame:Baseline to Study Completion (Up to 2 Weeks)

Cmax

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.